Fluicell

Fluicell Interest Expense

The Interest Expense of Fluicell (FLUI.ST) as of Nov 20, 2026 is 331,000.00 SEK. In the previous year, Interest Expense was 325,000.00 SEK — a change of 1.85% (higher).

Interest Expense

331,000.00SEK

YoY

1.85%

Last updated:

Interest Expense of Fluicell is 2024 331,000.00 SEK. Interest Expense of Fluicell was 2023 325,000.00 SEK. It decreases by 1.85% higher compared to the previous year.

The Fluicell Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2017
-34,000.00 SEK
Jan 1, 2018
78,000.00 SEK
Jan 1, 2019
48,000.00 SEK
Jan 1, 2020
-564,000.00 SEK
Jan 1, 2021
2,000.00 SEK
Jan 1, 2022
120,000.00 SEK
Jan 1, 2023
325,000.00 SEK
Jan 1, 2024
331,000.00 SEK
The Fluicell Interest Expense history
YEARInterest ExpenseYoY
331,000.00SEK+1.85%
325,000.00SEK+170.83%
120,000.00SEK+5,900.00%
2,000.00SEK-100.35%
-564,000.00SEK-1,275.00%
48,000.00SEK-38.46%
78,000.00SEK-329.41%
-34,000.00SEK-312.50%
16,000.00SEK-131.37%
-51,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Interest Expense of Fluicell is 331,000.00 SEK in 2024.

Interest Expense of Fluicell changed from 325,000.00 SEK to 331,000.00 SEK, representing a 1.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Fluicell since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Fluicell

All Key Metrics — Fluicell